Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) can infect several cells, replicate in the 48 central nervous system and affect blood-brain barrier (BBB) integrity. This study aimed to 49 investigate whether cerebrospinal fluid (CSF) EBV or CMV DNA was associated with viral, 50 inflammatory and neuronal damage biomarkers in people living with HIV (PLWH). 51 EBV, CMV DNA and HIV RNA were measured on CSF, through RT-PCR, from PLWHs 52 undergoing lumbar punctures for clinical reasons (excluding oncho-haematological 53 comorbidities). Immune-enzymatic assays evaluated BBB inflammation and damage. Patients 54 were stratified according to plasma HIV RNA levels in viremic (≥50 copies/mL) and aviremic 55 (<50 copies/mL). We included 298 participants. Among 167 viremic patients CSF EBV and 56 CMV DNA were detectable in 42 (25.1%) and 10 (6.3%) participants; among 130 aviremic 57 subjects CSF EBV and CMV DNA were detectable in 12 (9.2%) and 0 (0%) participants, 58 respectively. In viremic group detectable CSF EBV DNA was associated with CSF pleocytosis 59 (p<0.001), higher CSF HIV RNA (p<0.001) and neopterin levels (p=0.002). In aviremic 60 participants detectable EBV DNA was associated with pleocytosis (p=0.056), higher neopterin 61 (p=0.027) and immune globulins (p=0.016) in the CSF; CSF escape was more common in those 62 with detectable EBV DNA (50% vs 21.2%, p=0.036). 63 EBV DNA was frequently detected in the CSF of viremic and fewer aviremic patients on 64 antiretroviral treatment. In PLWH without clinical evidence of encephalitis CSF EBV DNA was 65 associated with higher levels of HIV RNA and biomarkers of neuronal damage/inflammation. 66The role of EBV reactivation in HIV-associated CNS disorders warrants further studies. 67 68 ha eliminato: 69 ha eliminato: The aim of this study was 70 ha eliminato: We examined CSF samples participants 71 undergoing lumbar punctures for clinical reasons 72